explore -WSS

explore

author：focus 2025-10-01 22:17:06 - browse：7

Truvian Health employee with a plate holding reagents used to measure commonly tested blood markers. Truvian

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

In a multisite study, the company tested nearly 240 blood samples from healthy donors and chronic disease patients for dozens of blood-based measurements commonly ordered by doctors, from cholesterol to blood sugar to blood cell counts. Results from Truvian’s benchtop analytical instrument, with few exceptions, closely matched readings from devices used in large central labs and made by Swiss pharma giant Roche and Japanese firm Sysmex.

The findings were presented at the annual meeting of the American Association for Clinical Chemistry, recently rebranded as the Association for Diagnostics & Laboratory Medicine. It’s the first time Truvian has shared clinical data on its product, though they have not been published in a peer-reviewed journal. The company, which is planning additional validation studies, expects to submit for Food and Drug Administration approval of its device by the third quarter of 2024.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

leisure time

focus

WSS

In rare move, senator releases unverified FBI source report alleging Biden bribe

Arc Institute generative AI designs new CRISPR systems

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

It's time to retire 'poor historian' from clinicians' vocabularies

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

hotspot

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

In rare move, senator releases unverified FBI source report alleging Biden bribe

The cancer drug shortage isn’t new — and neither are the solutions

A new ‘biological computer' targets cancer while sparing healthy cells

Novavax promises a turnaround & Lilly roils the obesity market

'CMA Fest' 2023: How to watch, who is performing and more

Peter Hotez and the public health issue of online harassment

Scientists grapple with ethics of stem cell research

At least 13 dead in Texas as scorching temps continue

Bird flu: Don't repeat Covid's 'health versus the economy' framing

explore

Cytokinetics CEO stresses company can launch heart drug on its own

Caribou posts encouraging results on off

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

After a decade, new Gardasil ad campaign gets it (mostly) right

Judge denies Trump's request for new trial in E. Jean Carroll case

Sanders wants to replace patents with prizes for drug inventions

leisure time

hotspot

focus

knowledge